These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22845334)

  • 21. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing emerging infectious threats to blood safety for the blood disorders community.
    Trimble SR; Parker CS; Grant AM; Soucie JM; Reyes N
    Am J Prev Med; 2010 Apr; 38(4 Suppl):S468-74. PubMed ID: 20331945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Time to introduce audit of transfusion treatment. Local transfusion committees should be established in Sweden].
    Schött U; Norda R; Ostlund I; Wikman A
    Lakartidningen; 2010 Dec 15-21; 107(50):3216-20. PubMed ID: 21294336
    [No Abstract]   [Full Text] [Related]  

  • 24. Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety.
    Leach Bennett J; Blajchman MA; Delage G; Fearon M; Devine D
    Transfus Med Rev; 2011 Oct; 25(4):267-92. PubMed ID: 21763103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linking human and animal health surveillance for emerging diseases in the United States: achievements and challenges.
    Lynn T; Marano N; Treadwell T; Bokma B
    Ann N Y Acad Sci; 2006 Oct; 1081():108-11. PubMed ID: 17135499
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: Application of a statistically representative sampling methodology to assess risk in US blood centers.
    Whitaker BI; Walderhaug M; Hinkins S; Steele WR; Custer B; Kessler D; Leparc G; Gottschall JL; Bialkowski W; Stramer SL; Dodd RY; Crowder L; Vahidnia F; Shaz BH; Kamel H; Rebosa M; Stern M; Anderson SA
    Transfusion; 2020 Sep; 60(9):1987-1997. PubMed ID: 32743798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moving on from voluntary non-remunerated donors: who is the best blood donor?
    Allain JP
    Br J Haematol; 2011 Sep; 154(6):763-9. PubMed ID: 21539535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Blood transfusion and supply chain management safety].
    Quaranta JF; Caldani C; Cabaud JJ; Chavarin P; Rochette-Eribon S
    Presse Med; 2015 Feb; 44(2):214-20. PubMed ID: 25578550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal transfusions.
    New HV; Stanworth SJ; Engelfriet CP; Reesink HW; McQuilten ZK; Savoia HF; Wood EM; Olyntho S; Trigo F; Wendel S; Lin Y; Hume H; Petäjä J; Krusius T; Villa S; Ghirardello S; von Lindern J; Brand A; Hendrickson JE; Josephson CD; Strauss RG; Luban NL; Paul W
    Vox Sang; 2009 Jan; 96(1):62-85. PubMed ID: 19121200
    [No Abstract]   [Full Text] [Related]  

  • 31. Trans people and blood donation.
    Goldman M; Butler-Foster T; Lapierre D; O'Brien SF; Devor A
    Transfusion; 2020 May; 60(5):1084-1092. PubMed ID: 32343438
    [No Abstract]   [Full Text] [Related]  

  • 32. AIDS and the blood supply: an analysis of law, regulation, and public policy.
    Salbu SR
    Wash Univ Law Q; 1996; 74(4):913-80. PubMed ID: 16273697
    [No Abstract]   [Full Text] [Related]  

  • 33. European strategies against the parasite transfusion risk.
    Reesink HW
    Transfus Clin Biol; 2005 Feb; 12(1):1-4. PubMed ID: 15814284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evolution of neonatal transfusion practices: current recommendations].
    Plaisant F
    Transfus Clin Biol; 2011 Apr; 18(2):262-8. PubMed ID: 21440478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The computer or electronic crossmatch.
    Butch SH; Oberman HA
    Transfus Med Rev; 1997 Oct; 11(4):256-64. PubMed ID: 9345707
    [No Abstract]   [Full Text] [Related]  

  • 36. [Evolution of the practices of labile blood product distribution].
    Tardivel R
    Transfus Clin Biol; 2005 Jun; 12(2):177-9. PubMed ID: 15894509
    [No Abstract]   [Full Text] [Related]  

  • 37. Emerging infectious disease agents and their potential threat to transfusion safety.
    Stramer SL; Hollinger FB; Katz LM; Kleinman S; Metzel PS; Gregory KR; Dodd RY
    Transfusion; 2009 Aug; 49 Suppl 2():1S-29S. PubMed ID: 19686562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood.
    Semple E; Bowes-Schmidt A; Yi QL; Shimla S; Devine DV
    Transfusion; 2012 Dec; 52(12):2683-91. PubMed ID: 22738255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International views on universal leucodepletion: the perspective in Germany.
    Seitz MD
    Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155
    [No Abstract]   [Full Text] [Related]  

  • 40. Strengthening the service continuum between transfusion providers and suppliers: enhancing the blood services network.
    Sime SL
    Transfusion; 2005 Oct; 45(4 Suppl):206S-23S. PubMed ID: 16181404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.